Tools
Tools
Abdel-Fatah, TMA, Rees, RC 
ORCID: https://orcid.org/0000-0002-4574-4746, Pockley, AG ORCID: https://orcid.org/0000-0001-9593-6431, Moseley, P, Ball, GR ORCID: https://orcid.org/0000-0001-5828-7129, Chan, SYT, Ellis, IO and Miles, AK ORCID: https://orcid.org/0000-0002-5388-938X,
2017.
The localisation of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.
Oncotarget, 8, pp. 112245-112257.
ISSN 1949-2553
Preview |
Text
9675_Pockley.pdf - Post-print Download (2MB) | Preview |
Abstract
Cancer biomarkers that can define disease status and provide a prognostic insight are essential for the effective management of patients with breast cancer (BC).
The prevalence, clinicopathological and prognostic significance of PRPF38B expression in a consecutive series of 1650 patients with primary invasive breast carcinoma were examined using immunohistochemistry. Furthermore, the relationship(s) between clinical outcome and PRPF38B expression was explored in 627 patients with ER-negative (oestrogen receptor) disease, and 322 patients with HER2-overexpressing disease.
Membranous expression of PRPF38B was observed in 148/1388 (10.7%) cases and was significantly associated with aggressive clinicopathological features, including high grade, high mitotic index, pleomorphism, invasive ductal carcinoma of no specific type (IDC-NST), ER-negative, HER2-overexpression and p53 mutational status (all p < 0.01). In patients with ER-negative disease receiving chemotherapy, nuclear expression of PRPF38B was significantly associated with a reduced risk of relapse (p = 0.0004), whereas membranous PRPF38B expression was significantly associated with increased risk of relapse (p = 0.004; respectively) at a 5 year follow-up. When patients were stratified according to ER-negative/HER2-positive status, membranous PRPF38B expression was associated with a higher risk of relapse in those patients that did not receive trastuzumab therapy (p = 0.02), whereas in those patients with ER-negative/HER2-positive disease that received trastuzumab adjuvant therapy, membranous PRPF38B expression associated with a lower risk of relapse (p = 0.00018).
Nuclear expression of PRPF38B is a good prognostic indicator in both ER-negative patients and ER-negative/HER2-positive BC (breast cancer) patients, whereas membranous localisation of PRPF38B is a poor prognostic biomarker that predicts survival benefit from trastuzumab therapy in patients with ER-negative/HER2-overexpressing BC.
| Item Type: | Journal article |
|---|---|
| Publication Title: | Oncotarget |
| Creators: | Abdel-Fatah, T.M.A., Rees, R.C., Pockley, A.G., Moseley, P., Ball, G.R., Chan, S.Y.T., Ellis, I.O. and Miles, A.K. |
| Publisher: | Impact Journals |
| Date: | 2017 |
| Volume: | 8 |
| ISSN: | 1949-2553 |
| Identifiers: | Number Type 10.18632/oncotarget.22496 DOI 22496 Publisher Item Identifier |
| Rights: | This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0). |
| Divisions: | Schools > School of Science and Technology |
| Record created by: | Jonathan Gallacher |
| Date Added: | 07 Dec 2017 15:57 |
| Last Modified: | 11 Oct 2021 13:13 |
| URI: | https://irep.ntu.ac.uk/id/eprint/32168 |
Actions (login required)
 |
Edit View |
Statistics
Views
Views per month over past year
Downloads
Downloads per month over past year
